(Total Views: 340)
Posted On: 03/02/2017 11:38:15 AM
Post# of 72447
The only thing I have found was this.
Feb 22, 2017
OTC Disclosure & News Service
-
BEVERLY, Mass., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and antibiotic applications, today announced progression of its ongoing Phase 2 clinical trial of Brilacidin to the third cohort (highest dose) for induction of remission of mild-to-moderate ulcerative colitis after satisfactory safety of prior cohorts was reported by the study’s Safety Committee. Patients included those with Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Disease (IBD).
Feb 22, 2017
OTC Disclosure & News Service
-
BEVERLY, Mass., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and antibiotic applications, today announced progression of its ongoing Phase 2 clinical trial of Brilacidin to the third cohort (highest dose) for induction of remission of mild-to-moderate ulcerative colitis after satisfactory safety of prior cohorts was reported by the study’s Safety Committee. Patients included those with Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Disease (IBD).
(0)
(0)
